

- Sub D*
3. (Amended) A method of Claim 1 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered sequentially.
- Fronted*
5. (Amended) A method of claim 1 [4] wherein the anti-tumor necrosis factor alpha antibody is administered in multiple doses.

- Sub D*
6. (Amended) A method of Claim 5 wherein the anti-tumor necrosis factor alpha antibody is a chimeric antibody.

- E*
7. (Amended) A method of Claim 6 wherein the chimeric antibody binds to one or more epitopes included in amino acid[s] of hTNF $\alpha$  selected from the group consisting of] residues of about 87-108 (SEQ ID NO:1) or [and] about 59-80 (SEQ ID NO:2) of hTNF $\alpha$ . set forth in SEQ ID NO:1 or SEQ ID NO:2.

- S*
8. (Amended) A method of Claim 6 wherein the chimeric antibody [binds to the epitope of] competitively inhibits binding of TNF $\alpha$  to monoclonal antibody cA2.

- 6*
9. (Amended) A method of Claim 6 wherein the chimeric antibody is monoclonal antibody cA2.

- Sub D*
10. (Amended) A method [for] of treating [or preventing] rheumatoid arthritis in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor alpha antibody to the individual, in therapeutically effective amounts.

11. (Amended) A method of Claim 10 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered simultaneously.

12. (Amended) A method of Claim 10 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered sequentially.
13. (Amended) A method of Claim 10 wherein the anti-tumor necrosis factor alpha antibody is administered in multiple doses.
14. (Amended) A method of Claim 13 wherein the anti-tumor necrosis factor alpha antibody is a chimeric antibody.
15. (Amended) A method of Claim 14 <sup>10</sup> wherein the chimeric antibody binds to one or more epitopes included in amino acid[s] of hTNF $\alpha$  selected from the group consisting of] residues of about 87-108 (SEQ ID NO:1) or [and] about 59-80 (SEQ ID NO:2) of hTNF $\alpha$ . set forth in SEQ ID NO:1 or SEQ ID NO:2.
16. (Amended) A method of Claim 14 <sup>10</sup> wherein the chimeric antibody [binds to the epitope of] competitively inhibits binding of TNF $\alpha$  to monoclonal antibody cA2.
17. (Amended) A method of Claim 16 <sup>12</sup> wherein the chimeric antibody is monoclonal antibody cA2.
18. (Amended) A method [for] of treating [or preventing] Crohn's disease in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor alpha antibody to the individual, in therapeutically effective amounts.
19. (Amended) A method of Claim 18 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered simultaneously.

- Jul 11
- A3
- E
- 18 20. (Amended) A method of Claim 18 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered sequentially.
- 19 21. (Amended) A method of Claim 18 wherein the anti-tumor necrosis factor alpha antibody is administered in multiple doses.
22. (Amended) A method of Claim 21 wherein the anti-tumor necrosis factor alpha antibody is a chimeric antibody.
23. (Amended) A method of Claim 22 wherein the chimeric antibody binds to one or more epitopes included in amino acid[s] of hTNF $\alpha$  selected from the group consisting of residues of about 87-100 (SEQ ID N:1) or [and] about 59-80 (SEQ ID NO:2) of hTNF $\alpha$ : set forth in SEQ ID NO:1 or SEQ ID NO:2.
24. (Amended) A method of Claim 22 wherein the chimeric antibody [binds to the epitope of] competitively inhibits binding of TNF $\alpha$  to monoclonal antibody cA2.
25. (Amended) A method of Claim 22 wherein the chimeric antibody is monoclonal antibody cA2.
26. (Amended) A composition comprising methotrexate and an anti-tumor necrosis factor alpha antibody or antigen-binding fragment thereof.
27. (Amended) A composition of Claim 26 wherein the anti-tumor necrosis factor alpha antibody is a chimeric antibody.
28. A composition of Claim 27 wherein the chimeric antibody binds to one or more epitopes included in amino acids [of hTNF $\alpha$  selected from the group consisting] of about 87-108 and about 59-80 of hTNF $\alpha$ . residues set forth in SEQ ID NO:1 or SEQ ID NO:2.
- 10/22/00